APTN ADAPTIN BIO, INC.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1938571 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-0.4%
TTM EPS YoY30.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-452.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets253.9%
Debt / equity—
Current ratio0.39x
Interest coverage-485.91x
Cash quality & payout
Operating cash flow / net income0.58x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $115,956 | $138,167 | $165,577 | $593,035 | $778,664 | $340,334 | $62,133 | $258,058 |
| SG&A expense | $838,419 | $1.06M | $978,576 | $774,983 | $896,948 | $1.18M | $788,325 | $250,022 |
| Operating income | -$954,375 | -$1.20M | -$1.14M | -$1.37M | -$1.68M | -$1.52M | -$850,458 | $1.91M |
| Interest expense | $2,966 | $4,696 | $1,943 | $0 | $0 | $0 | $72,659 | -$189,375 |
| Pretax income | -$957,341 | -$1.21M | -$1.15M | -$1.37M | -$1.68M | -$1.52M | -$603,084 | -$856,836 |
| Net income | -$957,341 | -$1.21M | -$1.15M | -$1.37M | -$1.68M | -$1.52M | -$603,084 | -$856,836 |
| EPS (basic) | -0.10 | -0.14 | -0.13 | — | -0.20 | -0.18 | -0.10 | — |
| EPS (diluted) | -0.10 | -0.14 | 0.13 | — | -0.20 | -0.18 | 0.10 | — |
| Weighted avg. shares (diluted) | 9.21M | 8.85M | 8.70M | — | 8.46M | 8.45M | 5.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $430,333 | $670,488 | $301,309 | $459,174 | $579,089 | $1.35M | $2.37M | $34,085 |
| Current assets | $1.09M | $981,452 | $706,117 | $619,159 | $979,474 | $1.66M | $2.85M | $45,539 |
| Total assets | $1.09M | $981,452 | $706,117 | $619,159 | $979,474 | $1.66M | $2.85M | $239,415 |
| Current liabilities | $2.76M | $2.65M | $2.48M | $2.11M | $1.86M | $1.19M | $1.11M | $4.34M |
| Total liabilities | $2.76M | $2.65M | $2.48M | $2.11M | $1.86M | $1.19M | $1.11M | $4.34M |
| Shareholders' equity | -$1.67M | -$1.67M | -$1.78M | -$1.49M | -$881,078 | $474,409 | $1.75M | -$4.10M |
| Shares outstanding | 9.26M | 9.05M | 8.79M | 8.66M | 8.46M | 8.46M | 8.40M | 3.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$964,551 | -$450,164 | -$596,298 | -$702,876 | -$772,430 | -$1.02M | -$2.28M | $112,653 |
| Financing cash flow | $724,396 | $819,343 | $438,433 | $582,961 | $0 | $0 | $4.62M | -$193,876 |
| Stock-based compensation | $184,359 | $193,806 | $345,396 | $176,739 | $320,125 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.